TF-ADC

TF-ADC (Tissue Factor Antibody-Drug Conjugate) refers to a class of targeted cancer therapeutics designed to deliver cytotoxic payloads specifically to cells expressing Tissue Factor (TF, also known as coagulation factor III or CD142). TF is a transmembrane glycoprotein frequently overexpressed in various solid tumors, including cervical, pancreatic, ovarian, and lung cancers, where it promotes tumor growth, angiogenesis, and metastasis. A typical TF-ADC consists of a monoclonal antibody targeting TF, conjugated via a linker to a potent cytotoxic agent, most commonly monomethyl auristatin E (MMAE). Upon binding to TF on the cell surface, the ADC is internalized, and the payload is released, leading to cell cycle arrest and apoptosis. The most prominent example in this class is tisotumab vedotin (Tivdak), which is FDA-approved for recurrent or metastatic cervical cancer. Research from the National Cancer Center Japan has also utilized TF-ADCs in preclinical models to study drug distribution and active targeting using advanced imaging techniques like microscopic mass spectrometry.

Other names

Tissue Factor Antibody-Drug Conjugateanti-TF ADC